CA2063593A1 - Constructs de fusion de la gelsoline multimerique - Google Patents

Constructs de fusion de la gelsoline multimerique

Info

Publication number
CA2063593A1
CA2063593A1 CA002063593A CA2063593A CA2063593A1 CA 2063593 A1 CA2063593 A1 CA 2063593A1 CA 002063593 A CA002063593 A CA 002063593A CA 2063593 A CA2063593 A CA 2063593A CA 2063593 A1 CA2063593 A1 CA 2063593A1
Authority
CA
Canada
Prior art keywords
gelsolin
fusion
moiety
polypeptide
multimeric
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002063593A
Other languages
English (en)
Inventor
R. Blake Pepinsky
Margaret D. Rosa
Thomas P. Stossel
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Biogen Inc
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2063593A1 publication Critical patent/CA2063593A1/fr
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70514—CD4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Liposomes
    • A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes, liposomes coated with polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4702—Regulators; Modulating activity
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/32—Fusion polypeptide fusions with soluble part of a cell surface receptor, "decoy receptors"
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/33—Fusion polypeptide fusions for targeting to specific cell types, e.g. tissue specific targeting, targeting of a bacterial subspecies

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Genetics & Genomics (AREA)
  • Epidemiology (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Virology (AREA)
  • Dispersion Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Cell Biology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Peptides Or Proteins (AREA)
  • Solid State Image Pick-Up Elements (AREA)
  • Transforming Light Signals Into Electric Signals (AREA)
  • Revetment (AREA)
  • Fats And Perfumes (AREA)
  • Consolidation Of Soil By Introduction Of Solidifying Substances Into Soil (AREA)
CA002063593A 1990-05-04 1991-05-03 Constructs de fusion de la gelsoline multimerique Abandoned CA2063593A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US52036890A 1990-05-04 1990-05-04
US520,368 1990-05-04

Publications (1)

Publication Number Publication Date
CA2063593A1 true CA2063593A1 (fr) 1991-11-05

Family

ID=24072299

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002063593A Abandoned CA2063593A1 (fr) 1990-05-04 1991-05-03 Constructs de fusion de la gelsoline multimerique

Country Status (5)

Country Link
EP (1) EP0481070A1 (fr)
JP (1) JPH05501503A (fr)
AU (1) AU8086191A (fr)
CA (1) CA2063593A1 (fr)
WO (1) WO1991017170A1 (fr)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1993025564A1 (fr) * 1992-06-15 1993-12-23 Brigham And Women's Hospital Peptides de fixation de phosphoinositides derives des sequences de gelsoline et villine
US5846743A (en) * 1995-02-22 1998-12-08 Brigham And Women's Hospital, Inc. Polyphoshoinositide binding peptides for intracellular drug delivery
WO1998004589A2 (fr) * 1996-07-30 1998-02-05 Biogen, Inc. Production de gelsoline plasmatique recombinante contenant un pont disulfure
AU7737196A (en) * 1996-11-14 1998-06-03 Brigham And Women's Hospital Polyphosphoinositide binding peptides for intracellular drug delivery
US6500646B1 (en) * 1996-12-27 2002-12-31 Mochida Pharmaceutical Co., Ltd. Cell membrane-directed drugs
US9408891B2 (en) 2003-11-12 2016-08-09 The Trustees Of The University Of Pennsylvania Methods of using gelsolin to treat or prevent bacterial sepsis
EP2335722B1 (fr) * 2004-05-12 2019-03-13 The Brigham and Women's Hospital, Inc. Utilisation de gelsoline pour traiter des infections
DK3279663T3 (da) 2006-03-15 2021-10-18 Brigham & Womens Hospital Inc Anvendelse af gelsolin til diagnosticering og behandling af inflammationssygdomme
US8440622B2 (en) 2006-03-15 2013-05-14 The Brigham And Women's Hospital, Inc. Use of gelsolin to treat multiple sclerosis and to diagnose neurologic disease (stossel)
US9575072B2 (en) 2008-01-25 2017-02-21 The Brigham And Women's Hospital, Inc. Diagnostic and therapeutic uses of gelsolin in renal failure

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4999344A (en) * 1987-11-06 1991-03-12 The United States Of America As Represented By The Secretary Of The Army Phosphatidyl treatment of rapidly proliferating cells

Also Published As

Publication number Publication date
EP0481070A1 (fr) 1992-04-22
AU8086191A (en) 1991-11-27
JPH05501503A (ja) 1993-03-25
WO1991017170A1 (fr) 1991-11-14

Similar Documents

Publication Publication Date Title
US5623053A (en) Soluble mammal-derived Fc receptor which binds at a pH ranging from about 5.5 to 6.5 and releases at a pH ranging from about 7.5 to 8.5
JP2799338B2 (ja) 機能的な第▲ｖ▼▲ｉ▼▲ｉ▼▲ｉ▼因子の製造方法
CA2457414C (fr) Chimeres de recepteur/proteine d'enveloppe virale et methodes d'utilisation associees
JPS63503275A (ja) ファクター８：ｃの製造方法
JP2006223316A (ja) 組換えフィブリン鎖、フィブリンおよびフィブリン−ホモログ
EP0465633A1 (fr) Proteines de fusion de proteines liantes c4
Kamboj et al. Identification of an octapeptide involved in homophilic interaction of the cell adhesion molecule gp80 of Dictyostelium discoideum
JP3805358B2 (ja) フォン・ウィルブランド因子の治療用ドメイン
CA2063593A1 (fr) Constructs de fusion de la gelsoline multimerique
AU752910B2 (en) CD8 as an inhibitor of the cellular immune system
AU648041B2 (en) Non-human primate CD4 polypeptides, fusions thereof, DNA encoding, and uses thereof
US8932601B2 (en) Hybrid and chimeric polypeptides that regulate activation of complement
EP0870040A2 (fr) Ligands de ciblage de vehicules pour l'apport de genes
EP1757614A1 (fr) Diagnostic et traitement des affections liées à la surcharge en fer et des affections ferriprives, procédés et compositions appropriés
WO1989003221A1 (fr) Agent antisyncytial
JPH11510687A (ja) α−βＣ４ＢＰ型の組換えヘテロ多量体タンパク質
EP0452433A1 (fr) Proteins inhibant la cytolyse (cti) et sequences adn codant pour lesdites proteines
KR100237582B1 (ko) Tpo 활성을 갖는 단백질의 제조방법
CA2094259A1 (fr) Fragments therapeutiques du facteur de von willebrand
Borghouts et al. Production and purification of monomeric recombinant peptide aptamers: requirements for efficient intracellular uptake and target inhibition
JP2000503532A (ja) 遺伝子送達ビヒクル標的化リガンド

Legal Events

Date Code Title Description
FZDE Dead